文献速递肝病消化道肿瘤与早癌

重新审视预防性糖皮质激素在肝细胞癌中减轻严重免疫相关不良事件的作用

Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2026-01-23

靶向CTLA-4与PD-1/PD-L1的双重免疫检查点抑制剂改变了不可切除肝细胞癌的治疗格局,但严重免疫相关不良事件高发限制了其应用。本文基于临床前与新兴临床证据,主张重新审视预防性糖皮质激素的禁用教条,认为审慎使用可能在不损害抗肿瘤活性的前提下减轻严重irAEs,尤其适用于含抗CTLA-4方案。

要点

  • 预防性糖皮质激素在肺癌免疫化疗中已常规使用,可减少严重irAEs且不折损疗效。
  • 肝细胞癌临床前研究显示激素预处理不损害双ICI诱导的T细胞激活与抗肿瘤活性。
  • 新兴临床数据提示基线或同期激素使用不负面影响HCC肿瘤学结局。

核心结论

  • 是时候重新思考ICI治疗中长期禁止预防性糖皮质激素的教条,审慎使用可能在不损害抗肿瘤活性的前提下减轻严重irAEs,尤其适用于含抗CTLA-4方案。

研究设计与样本

  • 专家意见类文章,基于临床前HCC研究、新兴临床数据及肺癌免疫化疗中预防性糖皮质激素的实践证据进行论述。

主要发现

  • 肺癌免疫化疗中预防性糖皮质激素与严重irAEs减少相关且不损害疗效。
  • 肝细胞癌临床前研究显示糖皮质激素预处理不损害双ICI诱导的T细胞激活或抗肿瘤活性。
  • 新兴临床数据提示基线或同期糖皮质激素使用不负面影响HCC肿瘤学结局。

临床怎么用

  • 在含抗CTLA-4的ICI方案中可考虑审慎使用预防性糖皮质激素以减轻严重irAEs。
  • 需开展前瞻性评估以明确预防性糖皮质激素在HCC中的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dual immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) or its ligand (PD-L1) have reshaped the treatment landscape of unresectable hepatocellular carcinoma (HCC). However, their clinical uptake remains limited by the high incidence of severe immune-related adverse events (irAEs), underscoring the urgent need for effective prophylactic strategies. Corticosteroids are traditionally viewed as antagonistic to antitumour immunity and have long been prohibited from prophylactic use in ICI-only regimens. Yet this dogma is increasingly at odds with both clinical practice and emerging evidence. Prophylactic corticosteroids (PC) are routinely administered in patients with lung cancer receiving immunochemotherapy, primarily to prevent chemotherapy-related toxicity. In this context, prophylactic corticosteroids have been associated with a reduction in severe irAEs without compromising efficacy. Our preclinical HCC studies demonstrate that corticosteroid premedication does not impair T-cell activation or antitumour activity induced by dual ICI therapy. Emerging clinical data similarly suggest that baseline or concomitant corticosteroid use does not adversely affect oncological outcomes in HCC. In this Expert Opinion, we argue that it is time to rethink the long-standing prohibition of prophylactic corticosteroids in ICI-based treatment. Judicious prophylactic corticosteroid use may offer a practical means to mitigate severe irAEs - particularly in anti-CTLA-4-containing regimens - while maintaining antitumour activity. We advocate for prospective evaluation of prophylactic corticosteroids in ICI-based regimens associated with higher immune-mediated toxicity, to better define their role in HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Shen YC, Pinato DJ, Liu TH, et al. Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma. J Hepatol. 2026. PMID: 41581763. doi:10.1016/j.jhep.2026.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。